Pharmaceuticals Subscribe

China Pharmaceuticals and Healthcare Report Q3 2016

Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

BMI View: Ongoing challenges facing multinational pharmaceutical firms in China will persist into 2016. This includes pricing pressures on off-patented pharmaceuticals, as authorities look to meet the unmet medical need in the country by expanding access to medicines while curbing […]

Costa Rica Pharmaceuticals and Healthcare Report Q3 2016

Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

BMI View: The approved loan from the World Bank will help improve the institutional management and organisation of healthcare delivery in Costa Rica’s public healthcare sector, as well as enhance the financial sustainability of Costa Rica’s universal health insurance scheme. […]

Cote d`Ivoire Pharmaceuticals and Healthcare Report Q3 2016

Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

BMI View: Côte d’Ivoire’s pharmaceutical and healthcare markets will be given a boost following signs of impressive economic growth and the government’s ongoing commitment to universal healthcare provision. We expect opportunities for innovative drugmakers to come into fruition over the […]

Cuba Pharmaceuticals and Healthcare Report Q3 2016

Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

BMI View: Pharmaceutical investment and commercial opportunities in Cuba will increase at a slow pace over the forecast period. Cuba’s biotechnology industry is set to benefit from the lifting of the US trade embargo, while the world-class Cuban medical research […]

Finland Pharmaceuticals and Healthcare Report Q3 2016

Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

BMI View: Finland’s economy is set to expand at the slowest rate in the eurozone in 2017. Reforms aimed at tackling its uncompetitive labour market will be insufficient to solve its bleak economic situation. This will force the government to […]

Austria Pharmaceuticals and Healthcare Report Q3 2016

Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

BMI View: GDP growth in Austria is forecast to accelerate to 1.8% in 2016 and 1.9% in 2017, after expanding by a moderate 0.6% over the past four years. This modest recovery comes after a long period of near-stagnation; Austria’s […]

India Pharmaceuticals and Healthcare Report Q3 2016

Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

BMI View: The tough operating environment for multinational drugmakers in India will see little improvement over the medium term. Designated as a ‘Priority Watch List Country’ for PhRMA’s Special 301 submission for 2016, the issues raised largely mirrored those touched […]

Belarus Pharmaceuticals and Healthcare Report Q3 2016

Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

BMI View: Belarus poses challenges for multinational drugmakers given government initiatives to reduce the reliance on medicinal imports. The weak ruble has seen prices of foreign medicines rise to unaffordable levels and has led to state intervention in the form […]

Italy Pharmaceuticals and Healthcare Report Q3 2016

Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

BMI View: SSN pharmaceutical expenditure will decline in 2016 – intensifying the revenue pressures for drugmakers and pharmacies in Italy, and increasing out-of-pocket costs for the population. The government remains committed to remaining under the 3% of GDP budget deficit […]

Belgium Pharmaceuticals and Healthcare Report Q3 2016

Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

BMI View: Belgium offers a stable pharmaceutical market with high per capita spending on medicines. However, drugmakers will increasingly find the government less willing to reimburse expensive, innovative medicines as it struggles to hit its fiscal targets. Headline Expenditure Projections […]